# A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

> **NCT06649695** · PHASE2 · RECRUITING · sponsor: **European Myeloma Network B.V.** · enrollment: 30 (estimated)

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** Teclistamab

## Key facts

- **NCT ID:** NCT06649695
- **Lead sponsor:** European Myeloma Network B.V.
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-02
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649695, "A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06649695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*